It has been about a month since the last earnings report for Cardiovascular Systems (CSII). Shares have added about 6.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Cardiovascular Systems due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Cardiovascular Systems Loss Wider Than Estimates in Q1
Cardiovascular Systems, Inc. reported a loss per share of 17 cents in first-quarter fiscal 2020, wider than the loss per share of 9 cents in the prior-year period. The reported figure was also wider than the Zacks Consensus Estimate of a loss of 9 cents.
Cardiovascular Systems’ revenues of $64.5 million in the first quarter marked a 14.6% year-over-year increase. Meanwhile, the top line beat the Zacks Consensus Estimate by 0.7%.
In the quarter under review, global Coronary device revenues jumped 26% year over year to $19 million. Domestic coronary revenues rose 17% to $16.3 million.
Global peripheral revenue increased 10% to $45.5 million, led by the launch of new peripheral orbital atherectomy devices. Domestic peripheral revenue increased 10% to $45.2 million.
Total U.S. revenues increased 12% to $61.5 million while International revenue totaled just under $3 million.
Gross margin in the reported quarter was 80.3%, down 85 basis points (bps) year over year on a 19.8% rise in cost of goods sold.
Meanwhile, selling, general and administrative (SG&A) expenses rose 13.4% to $46.8 million plus research and development (R&D) expenses escalated 46.2% to $10.8 million. As a result, operating expenses increased 18.3% to $57.5 million. Operating loss in the reported quarter came in at $5.7 million, wider than the operating loss of $2.9 million in the year-ago period.
The company exited first-quarter fiscal 2020 with cash and cash equivalents of $58.9 million compared with $74.2 million at the end of fiscal 2019.
Cardiovascular Systems reaffirmed its fiscal 2020 guidance. The company projects revenues within $278-$283 million for fiscal 2020, indicating 12% to 14% growth over fiscal 2019. The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at $280.4 million, below the company's view.
Moreover, the company reiterates gross profit margin at the band of 79-80%.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.